ERBB2 and neoplasm: Notably, novel antibody–drug conjugates like trastuzumab deruxtecan (T-DXd) have demonstrated substantial efficacy in HER2-low tumors (12), but their benefit could be limited if significant tumor fractions lack HER2 expression.